-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Scottish Drug Federation (SMC) has recommended the use of Cabometyx (cabozantinib) in combination with Opdivo (nivolumab) for the first-line treatment of adult advanced renal cell carcinoma (RCC) in the NHS in Scotland
.
Stage I-III renal cell carcinoma can be cured by surgical resection, but as many as one-third of patients will eventually relapse
.
In addition, about 15% of RCC patients have locally advanced or metastatic RCC at the time of treatment, and such RCC cannot be cured by surgery
In the phase III study, with a median follow-up of 18.
1 months , Cabometyx combined with Opdivo reduced the risk of death in patients with advanced RCC by 34% compared with the currently available sunitinib therapy
.
The study also reached the primary endpoint of progression-free survival (PFS).
In the phase III study, with a median follow-up of 18.
Figure 1.
Progression-free and overall survival in the intention-to-treat population
The 12-month overall survival probability for the Cabometyx combined with Opdivo group was 85.
7% (95% CI 81.
3-89.
1), and for sunitinib was 75.
6% (95% CI, 70.
5 to 80.
0) (hazard ratio of death 0.
60, P=0.
001)
.
55.
The 12-month overall survival probability for the Cabometyx combined with Opdivo group was 85.
Vascular Immunity
Original source:
Original source:http:// href="http://" target="_blank" rel="noopener">http:// http:// in this message
